AVANT (AVAN) Higher After Drug Increases Survival in Brain Tumor Patients

June 2, 2008 11:38 AM EDT

AVANT Immunotherapeutics (Nasdaq: AVAN) is on the move today after data presented at ASCO showed that the company and Pfizer's cancer vaccine, CDX-110, significantly increased survival time of patients with a deadly brain tumor.

In the ACTIVATE study, median survival time was 26 months (95% CI: 21.6, infinity) and median time-to-progression (TTP) was 14.2 months. Median survival in a historical matched cohort was 15.2 months (17/17) (95% CI: 13.9, 20.5).(p=0.0001) with median time to progression of 7.13 months (p=0,0001). No significant adverse events were seen in this study.

Preliminary results from the ACT II study currently estimate median overall survival to be 33.1 months, although the median has not yet been reached. The survival of a matched historical control group was 14.3 months (95% CI: 13.0, 16.2) and a subgroup treated with temozolomide (TMZ) of 15.2 months (95% CI: 13.9, 20.5 p=0.0078). Overall TTP was 16.6 months (95% CI: 10.8, infinity) compared with 6.4 months for the historical control group (95% CI: 5.0, 14.1). In this study, primary toxicity was reported as local injection site reactions.

Related Categories

FDA
Hot List

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?